Cervical cancer technology company, TruScreen Limited (NZAX:TRU), advises that effective 21 December 2017, the address of its registered office will change to:
c/- HLB Mann Judd Limited
Level 6, Equitable House
57 Symonds Street
For more information visit www.truscreen.com
Martin Dillon, TruScreen Chief Executive Officer
TruScreen real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN).TruScreen has distribution contracts in a range of international markets, including China, Latin America, Central Asia, Russia, the Middle East and Eastern Europe.